Dr Juanjo Infante | CEO
Vaxdyn

Dr. Infante is leading the development of a new class of vaccines to prevent antibiotic-resistant infections globally. The technology enables development of truly global vaccines, able to target at-risk populations in both high- and low-income countries, and has been developed with the support of the Boston based CARB-X accelerator. With additional support from the European Commision, the lead vaccine is facing the first-in-human trials while Vaxdyn is building partnerships for market access globally.

After an academic career that culminated in a senior researcher position at the University of Washington in Seattle, Dr. Infante served as Chief Scientific Officer at biotech companies developing vaccines and other biologics for human and animal health. He now leads Vaxdyn as the inventor of its patents and the architect of an international network of institutions collaborating on the development of global vaccines to raise immunity against the most concerning bacterial pathogens, starting with the prevention of disease caused by Klebsiella pneumoniae.